How Bayer Plans to Use AI for Key Decisions During Commercialization of Pipeline Assets

Today, data inundates every aspect of business, and discerning actionable insights is more challenging than ever. Faced with this challenge Dr. Anshuman Kelkar and the commercial team at Bayer want to be at the forefront, and he believes that by harnessing Artificial Intelligence (AI) the company would be able to swiftly navigate through this information-rich environment and make key business decisions. Anshuman will share his initial thinking about using the transformative approach to decision-making as it relates to new product commercialization.

This session explores concepts of AI as a catalyst for fitting complex data pieces together, mitigating risks, and maximizing impact. He will unravel how, much like identifying and fitting disparate parts to craft an automobile, AI serves as a pivotal tool in determining how to fit together the pieces of data to realize a coherent and successful product strategy—without a predefined blueprint.